- In September 2024, GSK plc announced that it has completed the primary objective data analysis from the phase II part of the TH HSV REC-003 trial to assess potential clinical efficacy of GSK3943104, an early-stage therapeutic herpes simplex virus (HSV) vaccine candidate
- In October 2023, Rational Vaccines (RVx) was awarded USD 2.8 million in National Institute of Health (NIH) funding to help further its research to diagnose, treat and prevent the spread of the Herpes Simplex Virus (HSV)
- In October 2023, Gilead Sciences, Inc. and Assembly Biosciences, Inc. announced a 12-year strategic partnership aimed at advancing the research and development of innovative antiviral therapies. The collaboration will initially focus on Assembly Bio’s established expertise in herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). In future, Gilead may opt-in to obtain exclusive rights for each of Assembly Bio’s current and future programs
- In February 2023, Maruho Co., Ltd received the manufacturing and marketing approval for a partial change of the indication and dosage/administration for anti-herpes virus agent "Amenalief Tab. 200mg" for the treatment of recurrent herpes simplex in Japan
- In August 2022, Rational Vaccines Inc. announced the launch of an observational clinical trial designed to determine the baseline characteristics of patients diagnosed with recurrent symptomatic herpes simplex virus type 2 (HSV-2)
- In January 2020, Candel Therapeutics, announced that it has acquired all oncolytic and other herpes simplex virus (HSV) based assets from PeriphaGen, Inc. This acquisition reinforces Candel’s leadership in viral therapies and accelerates the development of its rQNestin34.5, which is currently undergoing a Phase 1 study for recurrent malignant gliomas. The acquired development platform allows for precise modifications to the virus backbone, facilitating the customization of viral characteristics such as replication ability, tissue targeting, and the expression of various payloads, including immunomodulators
